TY - JOUR T1 - International BEAT-PCD Consensus Statement for Infection Prevention and Control for Primary Ciliary Dyskinesia in collaboration with ERN-LUNG PCD Core NETWORK and patient representatives JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00301-2021 SP - 00301-2021 AU - June K. Marthin AU - Jane S. Lucas AU - Mieke Boon AU - Carmen Casaulta AU - Suzanne Crowley AU - Damien M.S. Destouches AU - Ernst Eber AU - Amparo Escribano AU - Eric Haarman AU - Claire Hogg AU - Bernard Maitre AU - Gemma Marsh AU - Vendula Martinu AU - Antonio Moreno-Galdó AU - Huda Mussaffi AU - Heymut Omran AU - Petr Pohunek AU - Bernhard Rindlisbacher AU - Phil Robinson AU - Deborah Snijders AU - Woolf T. Walker AU - Panayiotis Yiallouros AU - Helle Krogh Johansen AU - Kim G. Nielsen Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/05/21/23120541.00301-2021.abstract N2 - Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD Network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative was now taken towards creating such consensus statement.Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment, and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process.Results We present a consensus statement on 20 IP&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current COVID-19 pandemic.Conclusion The first ever international consensus statement on IP&C intended specifically for PCD is presented and is targeted clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Lucas has nothing to disclose. ER -